• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 27, 2013

View Archived Issues

‘Good Week’ for Ablynx Continues: Discovery Deal with Merck Serono

LONDON – Ablynx NV notched up its second deal of the week, announcing a collaboration with Merck Serono under which a dedicated discovery unit will be set up at Ablynx. Read More

$45.1M Offering Puts a Smile on Fibrocell

Fibrocell Science Inc. went to the markets Thursday with an underwritten public offering of 11 million shares of common stock, priced at $4.10 apiece, seeking to generate $45.1 million. The price represented a hefty discount – 17.8 percent – to Wednesday’s closing price of $4.99 for Fibrocell’s shares (NYSE MKT:FCSC). Read More

The Federal Drug Tracking System Is Moving Toward Reality

A national track-and-trace system that would preempt the expanding patchwork of state regulations involving the drug supply chain may soon move a step closer to reality. Read More

Amino Casino: $15M Series A Bets on Arvinas’ Protein Work

It’s uninhibited. It’s degrading. It’s potentially a new class of drugs that does not just block disease proteins in cancer, but gets rid of them altogether. Read More

Boneheadedness Beneficial for Young and Old Minds

Scientists have discovered that the bone-derived hormone osteocalcin can cross both the placenta and the blood-brain barrier, and that it influences both prenatal brain development and adult brain function and behavior. Read More

Other News To Note

• Agenus Inc., of Lexington, Mass., entered a nonexclusive license agreement with Vaxlogic LLC, a subsidiary of Boca-Raton, Fla.-based Pharmlogic LLC, for the use of QS-21 Stimulon adjuvant in the development of select addiction, allergy and respiratory disease vaccine candidates. Read More

Stock Movers

Read More

Clinic Roundup

• Chimerix Inc., of Durham, N.C., published results of a Phase II study of brincidofovir (CMX001) for cytomegalovirus (CMV) in hematopoietic cell transplant (HCT) recipients in the Sept. 26, 2013, issue of the New England Journal of Medicine. The drug has shown broad-spectrum antiviral activity against double-stranded DNA viruses, including CMV. Read More

Pharma: Other News To Note

• Ipsen SA, of Paris, said it will relocate to Cambridge, Mass., next year in a move that follows the company’s takeover this summer of Syntaxin Ltd. Read More

U.S. Patent Disclosures

• Galectin Therapeutics Inc., of Norcross, Ga., was issued a U.S. Patent notice of issuance for 13/573,454, “Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.” Read More

Pharma: Clinic Roundup

• Eli Lilly and Co., of Indianapolis, disclosed positive patient-reported health outcomes from a Phase III trial of dulaglutide, an investigational, long-acting glucagon-like peptide 1 receptor agonist being studied as a once-weekly treatment for Type II diabetes. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe